Goldline Pharmaceutical Limited (BOM:544759)
India · Delayed Price · Currency is INR 32.98
+0.99 (3.09%)
At close: Oct 27, 2026
Goldline Pharmaceutical Revenue
In the fiscal year ending March 31, 2026, Goldline Pharmaceutical had annual revenue of 311.98M INR with 11.20% growth. Goldline Pharmaceutical had revenue of 97.91M in the quarter ending March 31, 2026. That makes Goldline Pharmaceutical the 41,244th largest company in the world by revenue and 4,073rd in India.
Revenue
311.98M
Revenue Growth
+11.20%
P/S Ratio
1.01
Revenue / Employee
2.48M
Employees
126
Market Cap
316.61M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 311.98M | 31.42M | 11.20% |
| Mar 31, 2025 | 280.56M | 44.90M | 19.05% |
| Mar 31, 2024 | 235.66M | 37.18M | 18.73% |
| Mar 31, 2023 | 198.48M | -41.62M | -17.33% |
| Mar 31, 2022 | 240.11M | 21.15M | 9.66% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Centuple Global | 5.62B |
| Dipna Pharmachem | 1.29B |
| Chandra Bhagat Pharma | 1.17B |
| VijayPD Ceutical | 1.00B |
| Medico Intercontinental | 838.36M |
| Medistep Healthcare | 708.31M |
| Zenlabs Ethica | 496.22M |
| Constronics Infra | 454.43M |